Alkem Laboratories

Bangalore, India

Alkem Laboratories

Bangalore, India
Time filter
Source Type

Yogesh D.B.,NIMS University | Shenoy D.B.,NIMS University | Srinivasa G.R.,Alkem Laboratories | Nagaraja G.,NIMS University | Baig F.,NIMS University
Der Pharma Chemica | Year: 2012

The (2-butyl -5-amino-3-benzofuranyl) 4-methoxy phenyl methanone amino acids have been synthesized by the reaction of (2-butyl -5-amino-3-benzofuranyl) 4-methoxy phenyl methanone with different hydrophobic amino acids were described (DBMY1-9). All the compounds were synthesized by conventional method and characterized by IR, 1H NMR and mass spectral data. The synthesized compounds were tested for antimicrobial activity against Staphylococcus aureus, Escherichia coli and pseudomonas aeruginosa. Among the synthesized compounds (2-butyl -5-amino-3-benzofuranyl) 4-methoxy phenyl methanone amino acids (DBMY-3,7,2) was found the most active derivative against S. aureus, E. coli and P. aeruginosa and The compounds DBMY-2, 3, 4 was found the most active derivative against Candida albicans and Asperigillus fumigatus respectively. The other Compounds exhibited moderate activity against the other test microorganisms.

Van De Merbel N.,Bioanalytical Laboratory | Savoie N.,Algorithme Pharma Inc. | Yadav M.,Alkem Laboratories | Ohtsu Y.,Astellas Pharma Inc. | And 5 more authors.
AAPS Journal | Year: 2014

This paper provides a comprehensive overview of stability-related aspects of quantitative bioanalysis and recommends science-based best practices, covering small and large molecules as well as chromatographic and ligand-binding assays. It addresses general aspects, such as the use of reference values, transferability and treatment of failing stability results, and also focuses on specific types of stability assessment: bench-top, freeze/thaw and long-term frozen stability, stock stability, extract stability, stability in whole blood, tissue and urine, and stability of endogenous analytes, in special matrix types and in incurred samples. © 2014 American Association of Pharmaceutical Scientists.

PubMed | SGPharma Pvt Ltd, Alkem Laboratories and Sharon Biomedicine Ltd
Type: Journal Article | Journal: Journal of wound care | Year: 2016

To develop and evaluate a biodegradable superporous hydrogel based wound healing composite of chitosan and alginate incorporated with curcumin and honey.A 3(2) factorial design was adopted to optimise the honey-curcumin hydrogel composite sponge (CHS). Sodium alginate and chitosan were dissolved in deionised water and 1% aqueous acetic acid solution at room temperature, respectively. Ethanolic solution of curcumin was poured into the chitosan solution followed by an addition of sodium alginate solution. In situ polymerisation was carried out by adding acrylamide base components to the polymeric solution of curcumin. Finally, honey was added with slow stirring and a sponge was cast on a glass surface by solvent evaporation at 45C. The produced sponge was assessed for swelling capacity, moisture loss, tensile strength, biocompatibility, bioadhesion, biodegradation, drug diffusion and wound healing properties. The morphology of CHS was studied by scanning electron microscopy (SEM).The optimised CHS demonstrated a high swelling capacity (111.05 05%), tensile strength (4323gm/mm(2)), in vitro drug diffusion (75.03 3.59%/20days), bioadhesion (20 0.2mg force) and ability of water vapour transmission. A rapid induction of tissue granulation and re-epithelialisation was observed. Time to complete healing (94.14 1.04% wound contraction) was 7 2 days.This study has shown that honey-curcumin hydrogel composite sponge can be formulated by a simple mixing and in situ polymerisation method. The hydrogel base provided a dry wound bed due to excellent fluid absorption capacity. Chitosan and honey contributed to effective faster wound healing. We recommend further clinical studies of the soft sponge wound healing composite for diabetic foot or pressure ulcers.

NEWARK, Calif., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation against all three filers of Abbreviated New Drug Applications (ANDAs) for Depomed's NUCYNTA franchise. With the court’s ruling, Depomed expects market exclusivity until December 2025 for NUCYNTA® ER, NUCYNTA® and NUCYNTA® oral solution (an unmarketed form of NUCYNTA). 1 “We are pleased with the Court’s decision as it confirms the validity and strength of the NUCYNTA patents,” said Jim Schoeneck, President and CEO of Depomed. “We look forward to growing the NUCYNTA franchise, comprised of two important and highly-differentiated medicines, for at least the next 9 years.” The court found U.S. patent Nos. 7,994,364 and RE39,593 to be valid and infringed by the defendants.  The patents cover the entire NUCYNTA franchise and will expire on December 27, 2025 and February 5, 2023, respectively.1  Judge Cecchi upheld the validity of U.S. Patent No. 8,536,130 (the “130 Patent”), but found that two of the three filers do not infringe the patent.  The ‘130 Patent covers NUCYNTA ER until March 2029. 1 The company intends to appeal the court’s finding as it relates to infringement of the ‘130 Patent. The defendants in the litigation included Actavis Inc., Alkem Laboratories Limited and Roxane Laboratories, Inc., along with certain of their affiliated companies.  All three defendants filed ANDAs for NUCYNTA ER and NUCYNTA.  An affiliate of Actavis filed an ANDA for NUCYNTA oral solution. Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of NUCYNTA ER and NUCYNTA, expectations regarding pediatric extensions applicable to the patents asserted in the litigation and other risks detailed in the company's Securities and Exchange Commission filings, including the company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. 1 Patent expiration dates reflect the addition of six months of pediatric patent term extension that Depomed anticipates securing from the FDA.

News Article | November 7, 2016

Notes:  Production, means the output of Carvedilol  Revenue, means the sales value of Carvedilol This report studies Carvedilol in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering  Aurobindo  Taj Pharmaceuticals  Ramdevchem  Polpharma  Wanbury  TAPI  Hainan Lvdao  Ningbo Tenet  Qilu Pharmaceutical  Juneng  Chongqin Huachuang  Zhejiang Jingxin  Chenxin  Guangzhou Nanxin  Lizhu  RPG Life Sciences Ltd  Medley Pharmaceuticals Ltd  Alkem Laboratories Ltd  Taurus Laboratories Pvt. Ltd  Nicholas Piramal India Ltd  Intas Laboratories Pvt Ltd  Zydus Cadila Healthcare Ltd  Micro Labs Ltd (Cardicare)  Themis Medicare Ltd Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Carvedilol in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India  Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Tablet  Film coated  Others  Split by application, this report focuses on consumption, market share and growth rate of Carvedilol in each application, can be divided into  AHeart Failure  BHypertension  COthers Global Carvedilol Market Research Report 2016  1 Carvedilol Market Overview  1.1 Product Overview and Scope of Carvedilol  1.2 Carvedilol Segment by Type  1.2.1 Global Production Market Share of Carvedilol by Type in 2015  1.2.2 Tablet  1.2.3 Film coated  1.2.4 Others  1.3 Carvedilol Segment by Application  1.3.1 Carvedilol Consumption Market Share by Application in 2015  1.3.2 AHeart Failure  1.3.3 BHypertension  1.3.4 COthers  1.4 Carvedilol Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Carvedilol (2011-2021) Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Humnabadkar V.,Astrazeneca | Madhavapeddi P.,Astrazeneca | Basavarajappa H.,Astrazeneca | Basavarajappa H.,Indiana University | And 9 more authors.
Journal of Biomolecular Screening | Year: 2015

Mycobacterium tuberculosis (Mtb) DNA gyrase ATPase was the target of a tuberculosis drug discovery program. The low specific activity of the Mtb ATPase prompted the use of Mycobacterium smegmatis (Msm) enzyme as a surrogate for lead generation, since it had 20-fold higher activity. Addition of GyrA or DNA did not significantly increase the activity of the Msm GyrB ATPase, and an assay was developed using GyrB alone. Inhibition of the Msm ATPase correlated well with inhibition of Mtb DNA gyrase supercoiling across three chemical scaffolds, justifying its use. As the IC50 of compounds approached the enzyme concentration, surrogate assays were used to estimate potencies (e.g., the shift in thermal melt of Mtb GyrB, which correlated well with IC50s >10 nM). Analysis using the Morrison equation enabled determination of Kiapps in the sub-nanomolar range. Surface plasmon resonance was used to confirm these IC50s and measure the Kds of binding, but a fragment of Mtb GyrB had to be used. Across three scaffolds, the dissociation half life, t1/2, of the inhibitor-target complex was ≤8 min. This toolkit of assays was developed to track the potency of enzyme inhibition and guide the chemistry for progression of compounds in a lead identification program. © 2014 Society for Laboratory Automation and Screening.

Shreenivas M.T.,Kuvempu University | Kumara Swamy B.E.,Kuvempu University | Manjunatha J.G.,Kuvempu University | Chandra U.,Kuvempu University | And 3 more authors.
Der Pharma Chemica | Year: 2011

In the present research work a series of isoxazole derivatives have been synthesized. The isoxazole derivatives are prepared starting from ethylacetoacetate with triethyl orthoformate followed by cyclization and hydrolysis of ester to form 5-Methylisoxazole-4-carboxylic acid. Further the acid is converted into acid chloride followed by condensation leads to a new series of 5-methyl-N-(substituted aryl) isoxazole-4- carboxamides (9 a-f, 13 a-c). The structures of newly synthesized compounds are confirmed on the basis of IR, 1H NMR of spectral data. The newly synthesized title compounds were screened for their in vitro antimicrobial activity. The compounds N-(2-chloro-5-nitrophenyl)-5-methylisoxazole-4-carboxamide (9 e) and N-(4-cyano-3-(trifluoro-methyl)-phenyl)-5-methylisoxazole-4-carbox-amide (9 f) are shown good antibacterial and anti fungal activity. The electrochemical reduction was carried out by using cyclic voltammetric technique and the effects of scan rate, sulphuric acid concentration and substitutents were studied. The overall electrode process was diffusion-controlled.

Shreenivas M.T.,Kuvempu University | Kumara Swamy B.E.,Kuvempu University | Srinivasa G.R.,Alkem Laboratories | Sherigara B.S.,Kuvempu University
Der Pharma Chemica | Year: 2011

A series of 4'-(2-n-Butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl-methyl-biphenyl-2-caboxylic acid- (4-phenyl/ substituted phenyl thiazole)-amide (VI a-g) were prepared. The structures of aminothiazole derivatives were confirmed on the basis of spectral data. The newly synthesized title compounds were screened for their in vitro antibacterial activity. Some of the compounds exhibited encouraging results.

Loading Alkem Laboratories collaborators
Loading Alkem Laboratories collaborators